

Predicting Tumor Mutational Burden and Survival in Head and Neck Squamous Cancer Patients Using Machine Learning and Bioinformatics Approaches

Nguyen-Kieu Viet-Nhi Taipei Medical University Taipei, Taiwan d142110002@tmu.edu.tw

Thi Thuy Nguyen Hue University of Medicine and Pharmacy, Hue City, Vietnam ntthuy.ub@hueuni.edu.vn Le Nguyen Quoc Khanh Taipei Medical University Taipei, Taiwan khanhlee@tmu.edu.tw

Tran Nguyen Anh Duy Can Tho University of Medicine and Pharmacy, Vietnam d142111006@tmu.edu.tw

How Tseng Taipei Medical University Taipei, Taiwan tsenghow@tmu.edu.tw Vu Cong Truc Uni of Medicine and Pharmacy at Ho Chi Minh City, Vietnam trucvucong@gmailcom

Nguyen Tu Thai Bao Can Tho University of Medicine and Pharmacy, Vietnam d142111005@tmu.edu.tw

Shih-Han Hung Taipei Medical University Taipei, Taiwan seedturtle@tmu.edu.tw

CCS CONCEPTS

• Applied Computing \rightarrow Machine Learning \rightarrow Computational Genomics \rightarrow Bioinformatics.

KEYWORDS

Tumor mutational burden; survival; head and neck squamous cancer; machine learning; bioinformatics

ACM Reference format:

Nguyen-Kieu Viet-Nhi, Le Nguyen Quoc Khanh, Vu Cong Truc, Nguyen Thi Thuy, Tran Nguyen Anh Duy, Nguyen Tu Thai Bao, How Tseng and Shih-Han Hung. 2023. Predicting Tumor Mutational Burden and Survival in Head and Neck Squamous Cancer Patients Using Machine Learning and Bioinformatics Approaches. In Houston '23: *The 14th ACM Conference on Bioinformatics, Computational Biology, and Health Informatics,* September 03-06, 2023, Houston, TX. ACM, New York, NY, USA, 1 page. https://doi.org/10.1145/3584371.3613038

ABSTRACT

Head and neck squamous cancer (HNSC) is a prevalent malignancy with a complex genetic profile. Tumor Mutational Burden (TMB) is an emerging biomarker associated with prognostic and therapeutic implications. In this study, we aimed to develop

Permission to make digital or hard copies of part or all of this work for personal or classroom use is granted without fee provided that copies are not made or distributed for profit or commercial advantage and that copies bear this notice and the full citation on the first page. Copyrights for third-party components of this work must be honored. For all other uses, contact the owner/author(s). *BCB'23, September 3-6, 2023, Houston, Texas USA* © 2023 Copyright held by the owner/author(s).

ACM ISBN 979-8-4007-0126-9/23/09

https://doi.org/10.1145/3584371.3613038

machine-learning models for predicting TMB and patient survival using RNA sequencing data and clinical features.

Methods: We collected RNA sequencing data and clinical information of HNSC patients from Gene Expression Omnibus (GEO) (GSE142083) and The Cancer Genome Atlas (TCGA) databases. Machine learning models, including Random Forest, Support Vector Machine (SVM), k-Nearest Neighbors (kNN), and Logistic Regression, were built to predict TMB levels based on patient gene expression profiles. The top 100 important features (genes) were selected from these models to create a survival prediction model.

Results: Among the tested models, Random Forest showed the highest accuracy (0.8011), followed by SVM (0.796), kNN (0.777), and logistic regression (0.704). Using the top 100 important genes, we developed a model to predict HNSC patient survival (under 3 years, 3-5 years, and over 5 years). Random forest achieved an accuracy of 0.70, while SVM and kNN reached 0.65. We identified five genes (KRT14, KRT6B, COL1A1, FN1, KRT6C) most closely related to TMB and patient survival. Through KEGG pathway analysis and neural network approaches, we discovered that these genes play a significant role in three pathways: PI3K-Akt signaling pathway, Human papillomavirus infection, and Bacterial invasion of epithelial cells.

In Conclusion, our study highlights the potential of machine learning in integrating bioinformatics for predicting TMB and patient survival in HNSC. The identified genes (KRT14, KRT6B, COL1A1, FN1, KRT6C) and related pathways may serve as potential biomarkers and therapeutic targets in HNSC treatment and prognosis.